Conatus Pharmaceuticals Stock Price - CNAT

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 0.34 ▼ -0.00 (-0.29%)
Company Name Stock Ticker Symbol Market Type
Conatus Pharmaceuticals Inc CNAT NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.024 -6.58% 0.341 0.375 0.34 0.3708 0.365 19:59:46
Bid Price Ask Price Spread Spread % News
0.34 0.4271 0.0871 20.39% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,098 527,181 $ 0.3608802 $ 190,249 818,377 0.25 - 6.735
Last Trade Time Type Quantity Stock Price Currency
17:48:22 formt 6,700 $ 0.34 USD

Conatus Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 11.31M 33.17M $ -18.01M -0.59 -0.79 32.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Conatus Pharmaceuticals News

Loading Messages....

Latest CNAT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CNAT Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.370.3960.340.3778480k-0.029-7.84%
1 Month0.30940.43670.290.36401M0.031610.21%
3 Months0.280.46490.25010.3503978k0.06121.79%
6 Months2.863.080.250.6521989k-2.519-88.08%
1 Year4.756.7350.251.7795910k-4.409-92.82%
3 Years2.389.40.253.8016794k-2.039-85.67%
5 Years6.3411.740.254.1523634k-5.999-94.62%

Conatus Pharmaceuticals Description

Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

Your Recent History
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.